304 related articles for article (PubMed ID: 37442076)
1. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease.
Wang J; Yang K; Zhang F; Yi Y; Wang J
Mult Scler Relat Disord; 2023 Sep; 77():104879. PubMed ID: 37442076
[TBL] [Abstract][Full Text] [Related]
2. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome.
Wendel EM; Thonke HS; Bertolini A; Baumann M; Blaschek A; Merkenschlager A; Karenfort M; Kornek B; Lechner C; Pohl D; Pritsch M; Schanda K; Schimmel M; Thiels C; Waltz S; Wiegand G; Anlar B; Barisic N; Blank C; Breu M; Broser P; Della Marina A; Diepold K; Eckenweiler M; Eisenkölbl A; Freilinger M; Gruber-Sedlmayr U; Hackenberg A; Iff T; Knierim E; Koch J; Kutschke G; Leiz S; Lischetzki G; Nosadini M; Pschibul A; Reiter-Fink E; Rohrbach D; Salandin M; Sartori S; Schlump JU; Stoffels J; Strautmanis J; Tibussek D; Tüngler V; Utzig N; Reindl M; Rostásy K;
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229191
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Martin K; Srikanth P; Kanwar A; Falardeau J; Pettersson D; Yadav V
Mult Scler Relat Disord; 2024 Jan; 81():105130. PubMed ID: 37979410
[TBL] [Abstract][Full Text] [Related]
4. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases.
Guzmán J; Vera F; Soler B; Uribe-San-Martin R; García L; Del-Canto A; Schlatter A; Salazar M; Molt F; Ramirez K; Marín J; Pelayo C; Cruz JP; Bravo-Grau S; Cárcamo C; Ciampi E
Mult Scler Relat Disord; 2023 Jan; 69():104442. PubMed ID: 36521387
[TBL] [Abstract][Full Text] [Related]
5. Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Gericke FC; Hanson JVM; Hackenberg A; Gerth-Kahlert C
Eur J Paediatr Neurol; 2024 Jan; 48():113-120. PubMed ID: 38217965
[TBL] [Abstract][Full Text] [Related]
6. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis.
Oliveira LM; Apóstolos-Pereira SL; Pitombeira MS; Bruel Torretta PH; Callegaro D; Sato DK
Mult Scler; 2019 Dec; 25(14):1907-1914. PubMed ID: 30417715
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
[TBL] [Abstract][Full Text] [Related]
8. High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
Lui A; Chong J; Flanagan E; Abrams AW; Krysko KM; Arikan B; Francisco C; Rutatangwa A; Waubant E; Ziaei A
Mult Scler Relat Disord; 2021 Nov; 56():103253. PubMed ID: 34517190
[TBL] [Abstract][Full Text] [Related]
9. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
[TBL] [Abstract][Full Text] [Related]
10. Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses.
Epstein SE; Levin S; Onomichi K; Langston C; Yeshokumar A; Fabian M; Sand IK; Klineova S; Lublin F; Dykstra K; Xia Z; De Jager P; Levine L; Farber R; Riley C; Vargas WS
Mult Scler Relat Disord; 2021 Nov; 56():103229. PubMed ID: 34479112
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
12. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.
Liyanage G; Trewin BP; Lopez JA; Andersen J; Tea F; Merheb V; Nguyen K; Lee FXZ; Fabis-Pedrini MJ; Zou A; Buckland A; Fok A; Barnett MH; Reddel SW; Marignier R; El Hajj A; Monif M; van der Walt A; Lechner-Scott J; Kermode AG; Kalincik T; Broadley SA; Dale RC; Ramanathan S; Brilot F;
J Neurol Neurosurg Psychiatry; 2024 May; 95(6):544-553. PubMed ID: 38290838
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.
Tanaka K; Kezuka T; Ishikawa H; Tanaka M; Sakimura K; Abe M; Kawamura M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686172
[TBL] [Abstract][Full Text] [Related]
14. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
15. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
16. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center.
Sutton P; Lutz MW; Hartsell FL; Kimbrough D; Tagg NT; Skeen M; Hudak NM; Eckstein C; Shah S
J Neuroimmunol; 2022 Dec; 373():577987. PubMed ID: 36272183
[TBL] [Abstract][Full Text] [Related]
17. Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report.
Kolcava J; Rajdova A; Vlckova E; Stourac P; Bednarik J
BMC Neurol; 2022 Aug; 22(1):313. PubMed ID: 36002821
[TBL] [Abstract][Full Text] [Related]
18. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
Burton JM; Youn S; Al-Ani A; Costello F
J Neurol; 2024 May; 271(5):2662-2671. PubMed ID: 38366070
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of cerebrospinal fluid oligoclonal band in anti-myelin oligodendrocyte glycoprotein (MOG) antibody associated disease.
Shao W; Liu X; Li J; Sheng T; Li Y; Gu Y; Deng B; Wang J; Yang W; Yu H; Zhang X; Chen X
Heliyon; 2024 Mar; 10(5):e24742. PubMed ID: 38434296
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
